- Home
- PUMP vs NUVB Comparison
PUMP vs NUVB Comparison
Compare PUMP & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUMP
- NUVB
- Stock Information
- Founded
- PUMP 2007
- NUVB 2018
- Country
- PUMP United States
- NUVB United States
- Employees
- PUMP N/A
- NUVB N/A
- Industry
- PUMP Oilfield Services/Equipment
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- PUMP Energy
- NUVB Health Care
- Exchange
- PUMP Nasdaq
- NUVB Nasdaq
- Market Cap
- PUMP 938.7M
- NUVB 774.1M
- IPO Year
- PUMP 2017
- NUVB N/A
- Fundamental
- Price
- PUMP $9.10
- NUVB $2.21
- Analyst Decision
- PUMP Buy
- NUVB Strong Buy
- Analyst Count
- PUMP 7
- NUVB 6
- Target Price
- PUMP $11.17
- NUVB $7.67
- AVG Volume (30 Days)
- PUMP 1.4M
- NUVB 1.7M
- Earning Date
- PUMP 02-19-2025
- NUVB 03-03-2025
- Dividend Yield
- PUMP N/A
- NUVB N/A
- EPS Growth
- PUMP N/A
- NUVB N/A
- EPS
- PUMP N/A
- NUVB N/A
- Revenue
- PUMP $1,444,286,000.00
- NUVB $2,162,000.00
- Revenue This Year
- PUMP N/A
- NUVB N/A
- Revenue Next Year
- PUMP N/A
- NUVB $374.06
- P/E Ratio
- PUMP N/A
- NUVB N/A
- Revenue Growth
- PUMP N/A
- NUVB N/A
- 52 Week Low
- PUMP $6.54
- NUVB $1.67
- 52 Week High
- PUMP $11.17
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- PUMP 48.05
- NUVB 37.58
- Support Level
- PUMP $8.75
- NUVB $2.16
- Resistance Level
- PUMP $9.22
- NUVB $2.38
- Average True Range (ATR)
- PUMP 0.37
- NUVB 0.12
- MACD
- PUMP 0.00
- NUVB 0.00
- Stochastic Oscillator
- PUMP 56.91
- NUVB 16.13
About PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and coiled tubing.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).